Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 308

1.

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

Tapiola T, Alafuzoff I, Herukka SK, Parkkinen L, Hartikainen P, Soininen H, Pirttilä T.

Arch Neurol. 2009 Mar;66(3):382-9. doi: 10.1001/archneurol.2008.596.

PMID:
19273758
2.

CSF markers for Alzheimer's disease: total tau, phospho-tau and Abeta42.

Andreasen N, Sjögren M, Blennow K.

World J Biol Psychiatry. 2003 Oct;4(4):147-55. Review.

PMID:
14608585
3.

Advances in the detection of Alzheimer's disease-use of cerebrospinal fluid biomarkers.

Sjögren M, Andreasen N, Blennow K.

Clin Chim Acta. 2003 Jun;332(1-2):1-10. Review.

PMID:
12763273
4.

Cerebrospinal fluid Abeta40 and Abeta42: natural course and clinical usefulness.

Shoji M.

Front Biosci. 2002 Apr 1;7:d997-1006. Review.

PMID:
11897565
5.

CSF total tau, Abeta42 and phosphorylated tau protein as biomarkers for Alzheimer's disease.

Blennow K, Vanmechelen E, Hampel H.

Mol Neurobiol. 2001 Aug-Dec;24(1-3):87-97. Review.

PMID:
11831556
6.

Amyloid beta protein and tau in cerebrospinal fluid and plasma as biomarkers for dementia: a review of recent literature.

Frankfort SV, Tulner LR, van Campen JP, Verbeek MM, Jansen RW, Beijnen JH.

Curr Clin Pharmacol. 2008 May;3(2):123-31. Review.

PMID:
18700307
7.
8.

Cerebrospinal fluid levels of A beta 42 and tau: potential markers of Alzheimer's disease.

Galasko D.

J Neural Transm Suppl. 1998;53:209-21. Review.

PMID:
9700659
9.

Cerebrospinal fluid biomarkers for Alzheimer's disease.

Blennow K, Zetterberg H.

J Alzheimers Dis. 2009;18(2):413-7. doi: 10.3233/JAD-2009-1177. Review.

PMID:
19661632
10.

Beta-amyloid (Abeta) protein in cerebrospinal fluid as a biomarker for Alzheimer's disease.

Andreasen N, Blennow K.

Peptides. 2002 Jul;23(7):1205-14. Review.

PMID:
12128078
12.

Cerebrospinal fluid tau, A beta, and phosphorylated tau protein for the diagnosis of Alzheimer's disease.

Formichi P, Battisti C, Radi E, Federico A.

J Cell Physiol. 2006 Jul;208(1):39-46. Review.

PMID:
16447254
13.
14.

[Biochemical markers for Alzheimer disease].

Czarna JM, Waldemar G, Heegaard NH.

Ugeskr Laeger. 2006 Mar 6;168(10):1010-4. Review. Danish.

PMID:
16522291
15.

[Alzheimer's disease as brain amyloidosis: diagnosis using cerebrospinal fluid abeta and tau].

Shoji M.

Rinsho Byori. 2006 May;54(5):503-8. Review. Japanese.

PMID:
16789421
16.

Cerebrospinal fluid biomarkers for diagnosis of Alzheimer's disease: beta-amyloid(1-42), tau, phospho-tau-181 and total protein.

Marksteiner J, Hinterhuber H, Humpel C.

Drugs Today (Barc). 2007 Jun;43(6):423-31. Review.

PMID:
17612711
17.

Biological markers in Alzheimer's disease.

Bailey P.

Can J Neurol Sci. 2007 Mar;34 Suppl 1:S72-6. Review.

PMID:
17469687
18.

Cerebrospinal fluid tau and beta-amyloid(1-42) in dementia disorders.

Vanmechelen E, Vanderstichele H, Hulstaert F, Andreasen N, Minthon L, Winblad B, Davidsson P, Blennow K.

Mech Ageing Dev. 2001 Nov;122(16):2005-11. Review.

PMID:
11589918
19.

CSF biomarkers for mild cognitive impairment.

Blennow K.

J Intern Med. 2004 Sep;256(3):224-34. Review.

20.

[Diagnosing the mild cognitive impairment stage of Alzheimer's disease].

Maruyama M, Matsui T, Tanji H, Ootsuki M, Nemoto M, Tomita N, Okamura N, Matsushita S, Higuchi S, Kodama M, Arai H, Sasaki H.

Seishin Shinkeigaku Zasshi. 2004;106(3):269-80. Review. Japanese.

PMID:
15164576

Supplemental Content

Support Center